Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Am J Clin Oncol. 2019 Oct;42(10):755–760. doi: 10.1097/COC.0000000000000599

Table 3.

Instances of toxicities possibly, probably, or definitely attributed to any protocol therapy in all patients (N=11).

Adverse Event Grades 1– 2 Grade 3 Grade 4
Hematologic
  Anemia 0 3 0
  Leukopenia 0 6 3
  Thrombocytopenia 0 4 0
  Lymphopenia 1 4 0
  Reduced ANC 0 5 5
General
  Dehydration 0 1 0
  Depression 0 1 0
  Somnolence 0 1 0
  Orthostasis 1 0 0
  Rash 1 0 0
  Hyperglycemia 0 1 0
  Hypokalemia 0 2 0
  Hyperkalemia 0 1 0
  Hyponatremia 0 1 0
  Sinusitis 0 1 0
Gastrointestinal
  Nausea 0 1 0
  Vomiting 0 1 0
  ALT elevation 0 2 1
  AST elevation 0 3 0
  Pancreatitis 0 1 0
Genitourinary
  Acute kidney injury 1 0 0
  Urinary tract infection 0 1 0
Respiratory
  Pneumonia 0 0 1
  Acidosis 0 1 1
  Sepsis 0 0 1
  Pleural effusion 0 0 1
  Acute respiratory distress syndrome 0 0 1
  Acute pulmonary edema 0 0 1
Cardiac*
  Myocarditis 0 0 1
  Heart failure 0 0 1
  Ventricular fibrillation 0 0 1
  Myocardial infarction 0 0 1
  Reduced ejection fraction 0 1 0
*

One patient died of cardiac causes after the first cycle of chemotherapy; this patient had not received any other protocol therapy.